@article{42a53e6af2ba4a60a3e723a12e806044,
title = "Emerging Poly-Agonists for Obesity and Type 2 Diabetes",
author = "Maximilian Kleinert and Christoffer Clemmensen and Kerstin Stemmer and M{\"u}ller, \{Timo D.\} and DiMarchi, \{Richard D.\} and Tsch{\"o}p, \{Matthias H.\}",
note = "Funding Information: Funding: This work is supported by the Danish Council of Independent Research/Medicine (5053-00155B), the Alfred Benzon Foundation, the Lundbeck Foundation, the Helmholtz Alliance ICEMED, the Helmholtz Initiative on Personalized Medicine iMed, the Helmholtz crossprogram topic “Metabolic Dysfunction,” the Alexander von Humboldt Foundation, the German Research Foundation DFG (SFB1123), and the European Research Council ERC (AdG HypoFlam no. 695054). Disclosure: RDD is a cofounder of several companies based on the discoveries of a variety of poly-agonists. MHT is a scientific advisor for Novo Nordisk, Bionorica SE, and Erx Biotech. The other authors declared no conflict of interest. Received: 4 May 2017; Accepted: 21 June 2017; Published online 26 September 2017. doi:10.1002/oby.21932",
year = "2017",
month = oct,
doi = "10.1002/oby.21932",
language = "English",
volume = "25",
pages = "1647--1649",
journal = "Obesity",
issn = "1930-7381",
publisher = "John Wiley and Sons Inc.",
number = "10",
}
